Navigation Links
Verenium Corporation To Announce Fourth Quarter And Year End 2012 Financial Results
Date:3/18/2013

nce as of December 31, 2012, near-term opportunities and long-term growth prospects, the impact of Verenium's restatement of certain of its historical financial statements on its consolidated balance sheets and consolidated statement of operations for the relevant periods and its cash position, and Verenium's San Diego facility and the related lease.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's audited financial results, capital expenditures and cash position for the year ended and as of December 31, 2012 being different from Verenium's estimated financial results, capital expenditures and cash position, the actual impact of Verenium's restatement of certain of its historical financial statements on its consolidated balance sheets and consolidated statement of operations for the relevant periods and its cash position being different from the estimated impact, Verenium's strategic focus, technologies, products and product candidates and product pipeline (including Verenium's ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, and market demand for those products and product candidates), dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, th
'/>"/>
SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Celladon Corporation Receives Notice of Allowance from United States Patent and Trademark Office
2. Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research
3. Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner
4. Eliza Corporation and BlueCross BlueShield of South Carolina Drive Awareness and Healthier Behavior to Increase Colorectal Cancer Screenings by 45 Percent
5. ShanghaiBio Corporation Partners with Ingenuity Systems to Address Challenges in Analysis and Interpretation of Genomics Data
6. Medbox, Inc. Announces Top-Tier Rating by Dun & Bradstreet Credibility Corporation
7. Scripps Research and Takeda Pharmaceuticals announce expanded research collaboration
8. Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia
9. Wake Forest Innovations Announces New Commercialization Developments
10. MARC Travel Awards announced for Immunohistochemistry and Microscopy (IHCM) Short Course 2013
11. FASEB MARC Travel Awards announced for the 2013 American College of Sports Medicine Northwest Chapter Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
(Date:7/31/2015)... 2015 The 10 th International Conference on ... October 22-25, 2015, in Shenzhen , ... celebrating its 10 th anniversary this year. Since its inauguration ... influential annual meetings in the ,omics, fields, and is one ... ICG-10 focuses on recent breakthroughs and advances in ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... and controversial technical barrier in stem cell biology, scientists ... Wisconsin-Madison have crafted a recipe that allows researchers to ... mouse-derived "feeder" cells, long thought to be a source ... The new findings, appear today (Feb. 17) in the ...
... other marine creatures, Aplysia, a common sea slug, enlists ... which such chemical attacks actually work against their intended ... has now shown that such chemical defenses can involve ... as components of chemical defense. , When attacked by ...
... by interfering with the biochemical signals one ovarian cell ... led by scientists at the USC/Norris Comprehensive Cancer Center ... of Southern California. , Their work is being published ... Biology. , "Before, we thought this gene was a ...
Cached Biology News:Scientists rid stem cell culture of key animal cells 2Scientists rid stem cell culture of key animal cells 3In the sea slug's defense against lobsters, confusion is key 2BRCA1 causes ovarian cancer through indirect, biochemical route 2BRCA1 causes ovarian cancer through indirect, biochemical route 3
(Date:7/31/2015)... ... 2015 , ... R-Biopharm is proud to announce the RIDASCREEN® ... foods, has been accepted by AOAC International as Official First Action method. The ... Products by R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Vieillard as Sales & Marketing Director. , With more than 25 years ... responsible for reinforcing Tronics’ business development activities worldwide. He brings to the company ...
(Date:7/30/2015)... Kan. , July 30, 2015   ... a pet therapeutics company focused on the licensing, ... companion animals, today announced that its strategic partner ... a dose confirmation study of AT-016, an adipose-derived ... for the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... LOUIS, July 30, 2015 HIGHLIGHTS:Q2 ... in 2014) , Reported sales were $697 million ... 2014.  Sales grew organically by 8%, and changes in ... acquisitions increased sales by 1%. , By business ... in Applied and 11% in SAFC Commercial. , ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... 21, 2012 International scientific and government experts ... potential use of Oxitec,s genetically modified Aedes aegypti ... The independent forum was co-organised by the Smithsonian ... Studies and the University of Panama. This brought together national ...
... ROCKVILLE, Md., May 21, 2012  Neuralstem, Inc. (NYSE ... President, will present at the World Stem Cells ... ) on Tuesday, May 22nd at 12:30 PM. ... Disorders," will review Neuralstem,s cellular therapy trial in ...
... 18, 2012 Champions Oncology Inc. (OTC: CSBR) announced ... Amendment (CLIA) certification from the Maryland Department of Health ... for the company to conduct medical laboratory tests. ... "Obtaining CLIA approval is a significant milestone for our ...
Cached Biology Technology:Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 2Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 3Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London 2Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities 2Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities 3
Rat CXCL7/Thymus Chemokine-1 DuoSet Economy Pack, 45 Plate...
Recombinant Rat Fas Ligand/TNFSF6...
FGF Receptor 1 Antibody...
Rabbit polyclonal to Kallikrein 1 ( Abpromise for all tested applications). Antigen: Full length native kallikrein from tissue (Human) Entrez Gene ID: 3816 Swiss Protein ID: P06870...
Biology Products: